Moo-yeal Lee

Biography

"Dr. Lee earned his Bachelor's Degree in Chemical Engineering from Gyeong Sang National University, South Korea, and a Master's Degree in Chemical and Biomolecular Engineering from KAIST (formerly known as Korea Advanced Institute of Science and Technology), where he also received his Ph.D. in Chemical and Biomolecular Engineering. Following graduation, he spent two years at Tokyo Institute of Technology, Japan, as a Postdoctoral Fellow supported by the Japan Society for the Promotion of Science, and three years at Rensselaer Polytechnic Institute, New York, as a Postdoctoral Research Scientist. Dr. Lee's work in microarray chip technology began as a lead senior scientist at Solidus Biosciences, Inc., a startup company that specialized in microarray chip technologies with applications in drug development. Dr. Lee has received A Successful Fellow of Korea-Japan Researchers' Friendship Award, and Postdoctoral Fellowships from the Japan Society for the Promotion of Science and the Korea Science and Engineering Foundation. His work has been highlighted by the Biological Research Information Center, a renowned research center in South Korea, and in other news outlets throughout the U.S. Through Cleveland State University, Solidus Biosciences, Inc., and Rensselaer Polytechnic Institute, Dr. Lee has focused on developing highly automatable, high-throughput microarray screening platforms and associated instruments and devices that can be used for biochemical and cell-based assays to assess human metabolism and toxicology. Specific areas of current research include various microarray biochip platforms such as carbohydrate, enzyme, virus, and cell-based microarrays. Dr. Lee's contributions, among others, include the metabolizing enzyme toxicology assay chip (MetaChip), the data analysis toxicology assay chip (DataChip), the metabolic stability assay chip (MesaChip), and the metabolism chip (TeamChip), with research funding from the National Science Foundation and the National Institutes of Health, as well as from L'Oreal, Pfizer, and Samsung Electro-Mechanics, Co. Dr. Lee has published 52 papers in peer-reviewed journals, 1 book, and 2 book chapters, and have 18 patents and patent applications. Dr. Lee's research goal at Cleveland State University is to develop innovative microarray biochip platforms and miniaturized biochemical and cell-based assays in droplets as small as 30 - 900 nanoliters for predictive, low-cost, high throughput evaluation of drug toxicity and efficacy. Dr. Lee envisions that ""microarray 3D bioprinting"" on the chip offers new opportunities for creating highly organized multicellular tissue constructs in vitro by dispensing multiple human cells in hydrogels layer-by-layer precisely with printing robots and mimicking the microenvironment of tissues in vivo, thereby potentially revolutionizing regenerative medicine, oncology, and drug discovery."

Research Interest

Microarray bioprinting/3D bioprinting, - Development of miniaturized biochemical and cell-based assays on a chip for drug discovery, - Gene transduction on a chip to emulate human liver for toxicology screening, - RNA interference on a chip to elucidate mechanisms of cellular responses for human toxicology, - Construction of miniaturized human tissues by printing primary human cell types for drug screening and personalized cancer therapy